Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare
company and leading manufacturer of plasma-derived medicines, today
officially celebrated the 50th anniversary of its flagship site in
Clayton, N.C., whose production of these essential therapeutics
during its existence has saved the lives of millions of patients.
Fifty years ago, the site opened as Cutter
Laboratories and produced modest quantities of a single medicine,
albumin, distributed domestically. Today, the Grifols Clayton
campus manufactures more than 14 million vials of plasma medicines
annually – about 40% of the company’s total global output – a
portfolio that now also includes immunoglobulins, both intravenous
and subcutaneous, as well as alpha-1 antitrypsin, specialty
proteins and blood clotting factors to treat patients all over the
world.
Situated on 700 acres (283 hectares), having
expanded tenfold since 1974, it is one of the world’s largest
plasma fractionation sites. Its present plasma processing capacity
of 12 million liters annually is more than half of the company’s
current global capability.
Acquiring the site from Talecris Biotherapeutics
in 2011 turned Grifols into a top-three plasma-sector powerhouse.
The company has strengthened its position considerably over the
ensuing years owing in large part to the manufacturing might of its
Clayton campus, in which Grifols has invested more than USD 1
billion to meet the growing demand for plasma therapeutics.
In the 13 years since the acquisition, Grifols
has quadrupled the site’s production capacity, during which time
the company’s global revenue has grown from EUR 1.8 billion to EUR
6.6 billion and global employee headcount has nearly doubled to
more than 23,000.
“The success of the Grifols Clayton
manufacturing site over the last 50 years is thanks to the great
work of the thousands of employees committed to helping patients
have more complete and fulfilling lives,” said Thomas Glanzmann,
Grifols Executive Chairman. “Ever since becoming part of Grifols,
Clayton has been a company crown jewel, a driver of innovative
medicines and sustainable manufacturing practices that has been a
major contributor to our growth over the last nearly 15 years.”
“Our Clayton site represents all that is special
about our company – trusted medicines, exceptional engineering,
sustainable operations and a committed workforce that gives its all
each and every day to make a positive impact on patients,” said
Nacho Abia, Grifols CEO. “As we celebrate this historic site’s
Golden Anniversary, we also look forward to all its future
achievements.”
A model of innovation
The site, which operates around the clock, 365
days a year, is an engineering marvel. Its industry-leading
advanced robotics span the entire plasma-medicine manufacturing
cycle, from fractionation to purification, to filling and packaging
of the final medicinal product. Innovations at Clayton are being
replicated today at new Grifols manufacturing sites in Montreal,
Canada, and Cairo, Egypt.
The North Carolina site’s technology has also
been on the front lines of recent public health crises. During the
COVID-19 pandemic, Clayton produced an anti-SARS-CoV-2 hyperimmune
globulin at a special-purpose facility equipped and staffed with
personnel trained in the production of plasma-derived medicines for
infectious diseases. This specialized knowledge was applied several
years earlier during an outbreak of Ebola, for which the Clayton
team produced anti-Ebola immunoglobulins.
Naturally sustainable
Within the Clayton campus, Grifols maintains a
300-acre (121 hectares) wildlife habitat area to protect and
enhance biodiversity. The reserve includes eight walking trails and
is home to more than 300 plant and animal species. This area holds
a GOLD conservation certification, the highest tier available from
the Wildlife Habitat Council.
In 2019, Grifols became the first pharmaceutical
company in the United States to receive the Zero-Waste-to-Landfill
validation from Underwriters Laboratories in recognition of the
Clayton site diverting 99% of its waste materials from landfills.
It has maintained this validation for the last five consecutive
years.
The site is also home to the first
LEED-certified building in Johnston County, where the town of
Clayton is located. Grifols’ campus here now has two LEED
facilities as well as two Green Globes buildings certified by the
Green Building Initiative (GBI), a nonprofit organization dedicated
to improving building performance and reducing climate impacts.
Grifols’ involvement in Johnston County includes
a broad range of programs and initiatives to help the local
communities. Since 2015, Grifols has promoted its ‘Discover the
Plasma,’ program, which it developed to enhance North Carolina
middle school science curricula while raising awareness about
plasma-derived medicines. Grifols is also a supporter of the
Johnston Community College Workforce Development Center, which it
helped create in 2005 and has since supported a state-of-the-art
simulated drug-manufacturing environment to train skilled employees
in Johnston County and help them find work locally.
Building on a legacy of
commitment
While always dedicated to the production of
plasma medicines, the Clayton site has operated under multiple
names throughout its 50-year history, first beginning operations as
Cutter Laboratories in 1974 before coming under the Miles
Laboratories umbrella in 1983. In 1995, the site began to operate
under the name of its parent company, Bayer, maintaining this brand
for a decade until Talecris Biotherapeutics purchased it in 2005.
Grifols acquired the Clayton site in 2011 and, with a mission to
improve the health and well-being of people around the world,
carried forward the site’s legacy of producing quality products to
benefit patients. Today, Grifols employs more than 1,600 people
onsite, with another 400 in nearby Research Triangle Park, the
largest research park in the U.S.
MEDIA CONTACTS:
Grifols Press Office
media@grifols.comTel. +34 93 571 00 02
SpainDuomo ComunicaciónTel.: +34 91 311 92 89 – +34 91 311 92
90Raquel Lumbreras (Tel. +34 659 572
185)Raquel_lumbreras@duomocomunicacion.com
Borja Gómez (Tel. + 34 659 572
185)Borja_gomez@duomocomunicacion.com
InvestorsInvestors Relations &
Sustainabilityinversores@grifols.com
- investors@grifols.comTel. +34 93 571 02 21
About Grifols
Grifols is a global healthcare company founded
in Barcelona in 1909 committed to improving the health and
well-being of people around the world. A leader in essential
plasma-derived medicines and transfusion medicine, the company
develops, produces, and provides innovative healthcare services and
solutions in more than 110 countries.
Patient needs and Grifols’ ever-growing
knowledge of many chronic, rare and prevalent conditions, at times
life-threatening, drive the company’s innovation in both plasma and
other biopharmaceuticals to enhance quality of life. Grifols is
focused on treating conditions across a broad range of therapeutic
areas: immunology, hepatology and intensive care, pulmonology,
hematology, neurology, and infectious diseases.
A pioneer in the plasma industry, Grifols
continues to grow its network of donation centers, the world’s
largest with over 390 across North America, Europe, Africa and the
Middle East, and China.
As a recognized leader in transfusion medicine,
Grifols offers a comprehensive portfolio of solutions designed to
enhance safety from donation to transfusion, in addition to
clinical diagnostic technologies. It provides high-quality
biological supplies for life-science research, clinical trials, and
for manufacturing pharmaceutical and diagnostic products. The
company also supplies tools, information and services that enable
hospitals, pharmacies and healthcare professionals to efficiently
deliver expert medical care.
Grifols, with more than 23,000 employees in more
than 30 countries and regions, is committed to a sustainable
business model that sets the standard for continuous innovation,
quality, safety, and ethical leadership.
The company’s class A shares are listed on the
Spanish Stock Exchange, where they are part of the Ibex-35
(MCE:GRF). Grifols non-voting class B shares are listed on the
Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs
(NASDAQ:GRFS).
For more information about Grifols, please visit
grifols.com
LEGAL DISCLAIMER
The facts and figures contained in this report
that do not refer to historical data are “future projections and
assumptions”. Words and expressions such as “believe”, “hope”,
“anticipate”, “predict”, “expect”, “intend”, “should”, “will seek
to achieve”, “it is estimated”, “future” and similar expressions,
in so far as they relate to the Grifols group, are used to identify
future projections and assumptions. These expressions reflect the
assumptions, hypotheses, expectations and predictions of the
management team at the time of writing this report, and these are
subject to a number of factors that mean that the actual results
may be materially different. The future results of the Grifols
group could be affected by events relating to its own activities,
such as a shortage of supplies of raw materials for the manufacture
of its products, the appearance of competitor products on the
market, or changes to the regulatory framework of the markets in
which it operates, among others. At the date of compiling this
report, the Grifols group has adopted the necessary measures to
mitigate the potential impact of these events. Grifols, S.A. does
not accept any obligation to publicly report, revise or update
future projections or assumptions to adapt them to events or
circumstances subsequent to the date of writing this report, except
where expressly required by the applicable legislation. This
document does not constitute an offer or invitation to buy or
subscribe shares in accordance with the provisions of the following
Spanish legislation: Royal Legislative Decree 4/2015, of 23
October, approving recast text of Securities Market Law; Royal
Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4
November, and any regulations developing this legislation. In
addition, this document does not constitute an offer of purchase,
sale or exchange, or a request for an offer of purchase, sale or
exchange of securities, or a request for any vote or approval in
any other jurisdiction. The information included in this document
has not been verified nor reviewed by the external auditors of the
Grifols group.
Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Oct 2023 to Oct 2024